Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

@article{Lip2012IndirectCO,
  title={Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.},
  author={Gregory Y H Lip and Torben Bjerregaard Larsen and Flemming Skj{\o}th and Lars Hvilsted Rasmussen},
  journal={Journal of the American College of Cardiology},
  year={2012},
  volume={60 8},
  pages={
          738-46
        }
}
OBJECTIVES This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative efficacy and safety against each other. BACKGROUND Data for warfarin compared against the new oral anticoagulants (OACs) in large phase III clinical trials of stroke prevention in atrial fibrillation (AF) are now available for the oral direct thrombin inhibitor, dabigatran etexilate, in 2 doses (150 mg twice daily [BID], 110 mg BID), and the… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 135 CITATIONS, ESTIMATED 36% COVERAGE

Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?

  • Trends in cardiovascular medicine
  • 2015
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Danger ahead: watch out for indirect comparisons!

  • Journal of the American College of Cardiology
  • 2012
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban

  • Advances in therapy
  • 2012
VIEW 3 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 10 Highly Influenced Citations

  • Averaged 7 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Ezekowitz MD, et al., for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation

SJ Connolly
  • N Engl J Med
  • 2009
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Wiviott SD, et al., for the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome

JL Mega, E Braunwald
  • N Engl J Med
  • 2012
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…